Cell Therapy
Tolerance Bio Secures $17.2M Seed Funding to Develop Thymus-Targeted Cell Therapies
Tolerance Bio, cell therapy, thymus, immune-mediated diseases, seed funding, allogeneic iPSC-based therapy
Astellas Reduces Universal Cells Workforce in Seattle, Relocates 12 Positions to Japan
Astellas, Universal Cells, layoffs, Seattle, Japan, cell therapy, biotech
Astellas Expands Cell Therapy Research with New Japan Site for Universal Cells
Astellas, Universal Cells, cell therapy, regenerative medicine, Japan research site, allogeneic cell therapy
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
Zephyrm Seeks Hong Kong IPO to Fund Phase III Cell Therapy Trials
Zephyrm, IPO, cell therapy, Phase III trials, Hong Kong listing
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta
Capricor Secures $35M Deal for European Rights to DMD Therapy Ahead of FDA Application
Capricor Therapeutics, Duchenne muscular dystrophy (DMD), cell therapy, FDA application, European rights, $35M deal
Adicet Bio Expands into Autoimmune Diseases with Allogeneic Gamma Delta T Cell Therapy
Adicet Bio, Autoimmune diseases, Allogeneic gamma delta T cell therapy, Lupus nephritis, Systemic lupus erythematosus (SLE), Cell therapy